SCHEMBL13119751

SCHEMBL13119751

COc1cc(Cl)cc(Oc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.59
CA4 P22748 1/20 0.50
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
NLRP3 Q96P20 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HTT P42858 2/20 0.42
MAPT P10636 1/20 0.42
PGR P06401 4/20 0.42
MAOB P27338 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TTR P02766 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18415521 0.89 LTA4H (0.73) LTA4HCA4TSHRSMN1; SMN2MEN1
SCHEMBL3789307 0.89 LTA4H (0.60) LTA4HTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL24628559 0.86 PGR (0.50) LTA4HSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL811027 0.85 LTA4H (0.60) LTA4HTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20411804 0.82 LTA4H (0.61) LTA4HCA4TSHRSMN1; SMN2MEN1
SCHEMBL30358262 0.82 LTA4H (0.61) LTA4HCA4TSHRSMN1; SMN2MEN1
SCHEMBL11174697 0.81 AHR (0.57) LTA4HSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL16659209 0.81 SMN1; SMN2 (0.62) LTA4HTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL10546649 0.80 SMN1; SMN2 (0.45) LTA4HSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL10544301 0.80 LTA4H (0.59) LTA4HCA4TSHRSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807684-B2 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-10-05 US disclosed
US-7807684-B2 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-10-05 US disclosed
WO-2007015809-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-02-08 WO disclosed
US-20070021442-A1 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. 2007-01-25 US disclosed
US-20070021442-A1 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021442-A1 HIV reverse transcriptase inhibitors POLRMT, RNGTT, POLR2E LTA4H 871/4885CA4 3542/4885TSHR 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.